Untch M, et al. - In the GeparQuinto phase III trial, it was shown that the addition of lapatinib to standard anthracycline–taxane chemotherapy compared with trastuzumab in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer resulted in a lower pathologic complete response (pCR; pT0 ypN0) rate. Researchers, herein, report the long-term outcomes. They noted that pCR correlated with long-term outcome. Furthermore, significantly improved survival was noted in patients who received prolonged anti-HER2 treatment (neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumab for 12 months) for hormone receptor–positive tumors, compared with those who received anti-HER2 treatment with trastuzumab alone.